Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:
“A major step forward for Egyptian women with triple-negative breast cancer (TNBC): Ministry of Health approval of adjuvant olaparib following chemotherapy.
With every new treatment opportunity comes a responsibility to ensure its optimal use.
Yesterday, we took a deep dive into the evidence behind olaparib, reviewing both the OlympiA trial and real-world data. What impressed me most was seeing our young oncologists critically analyze the data, question statistical outcomes, and discuss patient selection and toxicity management.
This is how we transform approvals into better patient outcomes—through education, curiosity, and a commitment to evidence-based care.
Proud of my team and their passion for learning.”
Other articles featuring Rasha Aboelhassan on OncoDaily.
